By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion reported today a 9 percent drop year over year in second-quarter revenues as licensing revenues retreated 62 percent.

For the three months ended June 30, total revenues were $304,000, down from $344,000 a year ago. While product revenues — comprised completely of sales of the company's OVA1 ovarian cancer test — rose more than 300 percent year over year to $191,000 from $45,000, license revenues fell to $113,000 from $299,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.